You are here

Home » Content

Pulmoner arteriyel hipertansiyon: tanı ve tedavisi

Pulmonary arterial hypertension: diagnosis and treatment

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Pulmonary arterial hypertension (PAH) is a rare disease of unknown etiology. Signs and symptoms of pulmonary arterial hypertension are often subtle and nonspecific. The diagnosis should be suspected in patients with increasing dyspnea on exertion and a known cause of pulmonary hypertension. Two-dimensional echocardiography with Doppler flow studies is the most useful imaging modality in patients with suspected pulmonary hypertension. If pulmonary hypertension is present, further evaluation may include assessment of oxygenation, pulmonary function testing, high-resolution computed tomography of the chest, ventilation-perfusion lung scanning and cardiac catheterization. Treatment with standart or combination therapy improve exercise capacity, quality of life, hemodynamics and long-term survival in patients with PAH. New agents are also under examination with affirmative results. Lung transplantation remains an option for selected patients with pulmonary arterial hypertension that does not respond to medical management.
Bookmark/Search this post with
Abstract (Original Language): 
Pulmoner arteriyel hipertansiyon (PAH), altta yatan, sebebi bilinmeyen nadir bir hastalıktır. Pulmoner arteriyel hipertansiyon bulguları belirgin olmadığından sessiz seyreder. Ancak eforla artan dispne şikayeti olan olgularda şüphe edildiğinde ve nedeni bilinen PH olgularında tanı konulabilmektedir. PH şüphe edilen olgularda, iki boyutlu Doppler ekokardiyografi en yararlı tanı yöntemlerinden biridir. PH varlığında ise oksijenizasyon, akciğer fonksiyon testleri, yüksek rezolüsyonlu bilgisayarlı tomografi, ventilasyon-perfüzyon sintigrafisi ve kardiyak kateterizasyon gibi ileri tetkiklerin yapılması gerekir. Standart veya kombine tedavilerle egzersiz kapasitesinde, yaşam kalitesinde, hemodinamide ve yaşam süresinde iyileşme saptanır. Yeni tedavi yöntemleri ve ajanlarla PAH tedavisinde yüz güldürücü sonuçlar elde edilmektedir. Akciğer transplantasyonu, tıbbi tedaviye cevap vermeyen pulmoner arteriyel hipertansiyonu olan seçilmiş hastalarda bir umut olarak durmaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-pulmoner-arteriyel-hipertansiyon-tani-tedavisi.pdf
  • 1
39-47
  • Turkish

REFERENCES

References: 

1. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment ofpulmonary arterial hypertension. J Am Coll Cardiol. 2004;43 (12 Suppl.):40-7
2.
Karabıyıkoğl
u G. Pulmoner arteriyel hipertansiyon. In: Karabıyıkoğlu G. ed. Pulmoner Hipertansiyon. Ankara, Antıp Basımevi; 2007;112-30
3. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. AmJMed. 1951;11(6):686-705
4. Rubin LJ. American College of Chest Physicians. Diagnosis and management ofpulmonary arterial hypertension: ACCP evidence-based clinical practice guıdelines. Chest2004;126 (1 Suppl):7-10
5. Stewart S. Pulmonary arterial hypertension. Oxon-England, Taylor and Francis Group,. 2005; 4¬45.
6. Tanabe N, Kimura A, Amano S, Okada O, Kasahara Y, Tatsumi K, et al. Association ofclinical features with HLA in chronic pulmonary tromboembolism. Eur Respir J. 2005;25(1):131-38.
7. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl):5-12.
8. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite suppressant drugs and the risk ofprimary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335(9):609-16.
9. D Langleben. The International Primary Pulmonary Hypertension Study Group (IPPHS). Familial primary pulmonaryhypertension. Chest 1994;105(2 Suppl):13-
16
10. Appelbaum L, Yigla M, Bendayan D, Reichart N, Fink G, Priel I, et al. Primary pulmonary hypertension in Israel:anational survey. Chest2001;119(6):1801-06
11. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir CritCareMed2006;173(9):1023-30
12. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, et al. Localization ofthe gene for familial primary pulmonary hypertension to chromosome 2q31-q32. NatGenet. 1997;15(3):277-80
13. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation. 1997; 95(12):2603-6
14. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000; 67(3):737-44
S.D.Ü. Tıp pak.
Derg
. 2009:16(1)/ 39-47
46
Öztürk, PAH: Tanı ve tedavisi
15. Nauser TD, Stites SW. Diagnosis and Treatment of echocardiography and right heart catheterization to assess Pulmonary Hypertension. Am Fam Physician. pulmonary hypertension in systemic sclerosis. Br J 2001;63(9):1789-98 Rheumatol. 1997;36(2): 239-43.
16. Lee SH. Rubin LJ. Current treatmnet strategies for 31. Penning S, Robinson KD, Major CA, Garite TJ. A pulmonary arterial hypertension. J Int Med. comparison ofechocardiography and pulmonary artery 2005;258:199-215 catheterization for evaluation ofpulmonary artery
17. Rich S, DantzkerDR, Ayres SM, BergofskyEH, pressuresinpregnantpatientswithsuspectedpulmonary Brundage BH, Detre KM, et al. Primary pulmonary hypertension. Am J Obstet Gynecol. hypertension. Anationalprospective study. AnnIntern 2001;184(7):1568-70
Med. 1987;107(2):216-23 32. GorcsanJ, Edwards TD, Ziady GM, Katz WE, Griffith
18. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon BP. Transesophageal echocardiography to evaluate MD, Frye RL, et al. Primary pulmonary hypertension: patients with severe pulmonary hypertension for lung natural history and the importance ofthrombosis. transplantation. Ann Thorac Surg. 1995;59(3):717-22. Circulation. 1984;70(4):580-7
19. BrownJW, HeathD, WhitakerW. Idiopathicpulmonary 33. Wax D, Garofano R, Barst RJ. Effects oflong-term hypertension. Br Heart J. 1957; 19(1):83-92 infusion ofprostacyclin on exercise performance in
20. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, patients with primary pulmonary hypertension. Chest. Brundage BH, Detre KM, et al. .Survival in patients 1999;116(4):914-20.
with primary pulmonary hypertension. Results from 34. Karabıyıkoğlu G. Kronik tromboembolik pulmoner a national prospective registry. Ann Intern Med. 1991; hipertansiyon: giriş ve hemodinami. In Metintaş M
115(5):343-9 (ed). Pulmonertromboemboli. Eskişehir, ASD Yayınları,
21. Trow TK, McArdle JR. Diagnosis ofpulmonary arterial 2001;253-64
hypertension. Clin Chest Med. 2007; 28(1): 59-73 35. Kuriyama K, Gamsu G, Stern RG, Cann CE, Hefkens
22. Bull, TM. Physical Examination in Pulmonary Arterial RJ, Brundage BH. CT-determined pulmonary artery Hypertension. Adv in Pulm Htn. 2005; 4(3) 6-10 diameters inpredictingpulmonaryhypertension. Invest
23. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth Radiol. 1984;19(1):16-22
S,
Higenbotta
m T, et al. Guidelines on diagnosis and 36. Remy-Jardin M, Remy J. Spiral CT angiography of treatment ofpulmonary arterial hypertension. The Task the pulmonary circulation 1999;212(3): 615-36.
Force on Diagnosis and Treatment ofPulmonary 37. Krüger S, Haage P, Hoffmann R, Breuer C, Bücker A, Arterial Hypertension ofthe European Society of Hanrath P, Günther RW. Diagnosis ofpulmonary arterial
Cardiology. Eur Heart J. 2004;25(24):2243-78 hypertension and pulmonary embolism with magnetic
24. Hoeper MM, Rubin LJ. Update in pulmonary resonance angiography. 2001;120(5):1556-61 hypertension 2005. Am J Respir Crit Care Med. 38. Oudiz RJ, Langleben D. Cardiac catheterization in 2006;173(5): 499-505 pulmonary arterial hypertension: an updated guide to
25. Rubin LJ. Pulmonary arterial hypertension. Proc Am proper use. Adv in Pulm Htn. 2005;4(3):15-25 Thorac Soc. 2006;3(1):111-15 39.Nootens M, Wolfkiel CJ, Chomka EV, Rich S.
26. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr Understanding right and left ventricular systolic function C, Vogeser M, Jürgen Behr J. Characterization ofbrain and interactions at rest and exercise in primary natriuretic peptide in long-term follow-up ofpulmonary pulmonary hypertension. Am J Cardiol. 1995;75(5): arterial hypertension. Chest. 2005;128(4):2368-74 374-77
27. Akkoca YÖ. Pulmoner hipertansiyonda solunum 40. Shapiro BP, Nishimura RA, McGoon MD, Redfield fonksiyon testleri, arter kan gazları ve egzersiz testleri. MM. Diagnostic dilemmas: diastolic heart failure In: Karabıyıkoğlu G. ed. Pulmoner Hipertansiyon. causing pulmonary hypertension and pulmonary Ankara, Antıp Basımevi, 2007;112-30 hypertension causing diastolic dysfunction. Adv in
28. Patrat JF, Jondeau G, Dubourg O, Lacombe P, Rigaud Pulm Htn 2006;5(1):13-20.
M,
Bourdaria
s JP, et al. Left main coronary artery 41. Bressollette E, Dupuis J, Bonan R, Doucet S, Cernacek compression during primary pulmonary hypertension. P, Tardif JC. Intravascular ultrasound assessment of
Chest. 1997;112(3):842-43. pulmonaryvascular disease inpatients withpulmonary
29. McGoonM, GuttermanD, SteenV, BarstR, McCrory hypertension. 2001;120(3):809-15
DC, Fortin TA, et al. Screening, early detection, and 42. Bush A, Gray H, Denison DM. Diagnosis ofpulmonary diagnosis of pulmonary arterial hypertension: ACCP hypertension from radiographic estimates ofpulmonary
evidence-basedclinicalpracticeguidelines. Chest. arterialsize. 1988;43(2):127-31
2004;126(1 Suppl):14-34 43. NaeijeR,VachieryJL. Medicaltherapyofpulmonary
30. Denton CP, Cailes JB, Phillips GD, Wells AU, Black hypertension: conventional therapies. Clin Chest Med. CM, Bois RM. Comparison ofDoppler 2001;22(3):517-27.
S.D.Ü. Tıp pak.
Derg
. 2009:16(1)/ 39-47
Öztürk, PAH: Tanı ve tedavisi
47
44. Weissmann N, Tadic A, Hânze J, Rose F, Winterhalder S, Nollen M, et al. Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? Am J Physiol Lung Cell Mol Physiol. 2000;279(4):683-90
45. Alam S, Palevsky HI. Standard therapies for pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):91-115
46. Yu L, Quinn DA, Garg HG, Hales CA. Gene expression ofcyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun. 2006;345(4):1565-72
47. Hassoun PM, Thompson BT, Steigman D, Hales CA. Effect ofheparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig. Am Rev Respir Dis. 1989; 139(3):763-68
48. Garg HG, Hales CA, Yu L, Butler M, Islam T, Xie J, Linhardt RJ, et al. Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative. Carbohydr Res. 2006;341(15):2607-12
49. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison ofcontinuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334(5):296-302
50. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum ofdisease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-34
51. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-29
52. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion oftreprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-4.
53. Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir CritCare Med.2005;172(12):1586-9
54. O'Callaghan D, Gaine SP. Bosentan: a novel agent for the treatment ofpulmonary arterial hypertension. Int J Clin Pract. 2004;58(1):69-73.
55. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol.
2005;46(3):529-35.
56. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al. Treatment ofpulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47(10):2049-56
57. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005; 25(2):244-49
58. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169(4):441-7
59. Wharton J, Strange JW, M0ller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172(1):105-13
60. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57

Thank you for copying data from http://www.arastirmax.com